Skyclarys Denied for Irish Patients | Ireland News

A life-changing drug for Friedreich’s Ataxia, costing €280,000 per patient annually, faces rejection by Ireland’s HSE Drugs Group—despite hope from families like Craig Coady’s, who lost his son Rory to the disease and now fear losing access to treatment for his younger son Paudie. While ten other countries already cover Skyclarys, Ireland’s final decision looms, with senior HSE officials set to decide on August 25th—potentially turning a medical breakthrough into a heartbreaking denial for those fighting for survival and dignity. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/bb2699de2f3d3aac